Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Henry Schein Has Agreed To Acquire A Majority Interest In TriMed, A Developer Of Solutions For Orthopedic Treatment Of Lower Extremities (Foot And Ankle) And Upper Extremities (Primarily Hand And Wrist); Deal Terms Were Not Disclosed

Author: Benzinga Newsdesk | December 20, 2023 08:02am

TriMed had 2022 net sales of approximately $48 million. The transaction is subject to certain regulatory approvals and closing conditions, and is expected to be completed in the first quarter of 2024

Posted In: HSIC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist